Journal Home
Search for

Volume 144, Issue 1, Pages 35-42 (July 2009)


View previous. 14 of 36 View next.

Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2)

Robert H. DworkinaCorresponding Author Informationemail address, Dennis C. Turkb, Dennis A. Revickic, Gale Hardingc, Karin S. Coynec, Sarah Peirce-Sandnerd, Dileep Bhagwate, Dennis Evertone, Laurie B. Burkef, Penney Cowang, John T. Farrarh, Sharon Hertzf, Mitchell B. Maxi, Bob A. Rappaportf, Ronald Melzackj

Received 26 February 2008; received in revised form 11 February 2009; accepted 12 February 2009. published online 08 April 2009.

Refers to article:
All in one: Is it possible to assess all dimensions of any pain with a simple questionnaire? , 27 April 2009
Didier Bouhassira, Nadine Attal
PAIN®
July 2009 (Vol. 144, Issue 1, Pages 7-8)
Full Text | Full-Text PDF (79 KB)

Abstract 

The objective of the present research was to develop a single measure of the major symptoms of both neuropathic and non-neuropathic pain that can be used in studies of epidemiology, natural history, pathophysiologic mechanisms, and treatment response. We expanded and revised the Short-form McGill Pain Questionnaire1 (SF-MPQ) pain descriptors by adding symptoms relevant to neuropathic pain and by modifying the response format to a 0–10 numerical rating scale to provide increased responsiveness in longitudinal studies and clinical trials. The reliability, validity, and subscale structure of the revised SF-MPQ (SF-MPQ-21) were examined in responses from 882 individuals with diverse chronic pain syndromes and in 226 patients with painful diabetic peripheral neuropathy who participated in a randomized clinical trial. The data suggest that the SF-MPQ-2 has excellent reliability and validity, and the results of both exploratory and confirmatory factor analyses provided support for four readily interpretable subscales—continuous pain, intermittent pain, predominantly neuropathic pain, and affective descriptors. These results provide a basis for use of the SF-MPQ-2 in future clinical research, including clinical trials of treatments for neuropathic and non-neuropathic pain conditions.

a Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642, USA

b Department of Anesthesiology, University of Washington, Seattle, WA, USA

c United Biosource Corporation, Bethesda, MD, USA

d Department of Anesthesiology, University of Rochester, Rochester, NY, USA

e EpiCept Corporation, Tarrytown, NY, USA

f United States Food and Drug Administration, Bethesda, MD, USA

g American Chronic Pain Association, Rocklin, CA, USA

h Department of Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA

i Department of Anesthesiology, University of Pittsburgh, Pittsburgh, PA, USA

j Department of Psychology, McGill University, Montreal, Canada

Corresponding Author InformationCorresponding author. Tel.: +1 585 275 3524; fax: +1 585 473 5007.

1 Copyright: SF-MPQ, R. Melzack; SF-MPQ-2, R. Melzack and the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT).

PII: S0304-3959(09)00125-0

doi:10.1016/j.pain.2009.02.007


View previous. 14 of 36 View next.